Aurinia Pharmaceuticals Inc
AUPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.07B
Close$
$7.01
56.5% downside
Current Fair Value
56.5% downsideOvervalued by 56.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.07 Billion |
|---|---|
| Enterprise Value | $1.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.14 |
| Beta | 1.41 |
| Outstanding Shares | 130,081,000 |
Return
| Return on Equity | 51.09% |
|---|---|
| Return on Assets | 39.65% |
| Return on Invested Capital | 23.56% |
Valuation & Multiples
| P/E Ratio | 6.82 |
|---|---|
| PEG | 9.23 |
| Price to Sales | 8.05 |
| Price to Book Ratio | 4.03 |
| Enterprise Value to Revenue | 6.3 |
| Enterprise Value to EBIT | 12.03 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$80.45 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$82.86 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.5381▲ 273.49% |
|---|---|
| Total Calls | 380,600▲ 4.05% |
| Total Puts | 1,346,600▲ 358.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.02%▲ 5.12% |
|---|---|
| Total Invested | $1.35B▲ 22.80% |
| Investors Holding | 294▲ 18.00% |
ESG Score
No data
About Aurinia Pharmaceuticals Inc
CEO: Peter Greenleaf